Analysts expect that Aldeyra Therapeutics Inc (NASDAQ:ALDX) will announce earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.31). Aldeyra Therapeutics reported earnings per share of ($0.51) during the same quarter last year, which indicates a positive year over year growth rate of 35.3%. The company is expected to report its next quarterly earnings results on Monday, May 8th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($2.22) to ($1.31). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.81) per share, with EPS estimates ranging from ($2.60) to ($1.47). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Thursday, March 30th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.30.
A number of equities research analysts have issued reports on ALDX shares. Canaccord Genuity set a $15.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a report on Sunday, December 25th. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Tuesday, January 3rd. Cowen and Company reissued a “buy” rating and set a $20.00 target price on shares of Aldeyra Therapeutics in a report on Friday, March 31st. Finally, HC Wainwright set a $18.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a report on Saturday, April 1st. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $14.30.
WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/05/20/0-33-eps-expected-for-aldeyra-therapeutics-inc-aldx-this-quarter-updated-updated-updated.html.
Aldeyra Therapeutics (NASDAQ:ALDX) traded down 16.35% during mid-day trading on Monday, reaching $4.35. The company’s stock had a trading volume of 1,832,901 shares. The firm has a 50 day moving average price of $5.05 and a 200 day moving average price of $5.46. Aldeyra Therapeutics has a 52-week low of $4.10 and a 52-week high of $8.19. The company’s market cap is $27.17 million.
In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 893,025 shares of the stock in a transaction on Tuesday, February 14th. The shares were acquired at an average price of $4.50 per share, with a total value of $4,018,612.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Todd C. Brady bought 22,223 shares of the stock in a transaction on Friday, February 17th. The shares were acquired at an average cost of $4.50 per share, for a total transaction of $100,003.50. Following the acquisition, the insider now directly owns 64,408 shares in the company, valued at $289,836. The disclosure for this purchase can be found here. Insiders have acquired a total of 923,025 shares of company stock worth $4,153,613 in the last three months. Insiders own 28.40% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP acquired a new stake in shares of Aldeyra Therapeutics during the third quarter worth about $1,110,000. Knoll Capital Management LP acquired a new stake in shares of Aldeyra Therapeutics during the third quarter worth about $1,038,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth about $10,381,000. 48.60% of the stock is currently owned by institutional investors and hedge funds.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.